Zevra Therapeutics (ZVRA) Change in Acquisitions & Divestments (2016 - 2026)

Zevra Therapeutics has reported Change in Acquisitions & Divestments for 9 years, with the latest figure at $94.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments rose 422.07% year-over-year to $94.0 million; the trailing twelve-month figure through Mar 2026 stood at $254.5 million (up 802.16% YoY), and the FY2025 full-year result was $178.5 million, up 614.0% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $94.0 million, up from $87.5 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $94.0 million in Q1 2026, with the low at $202000.0 in Q4 2024.
• Historically, Change in Acquisitions & Divestments has averaged $29.4 million across 5 years, with a median of $14.8 million in 2024.
• Annual changes were most pronounced in 2024 — Change in Acquisitions & Divestments tumbled 98.71% — and 2025, when it jumped 43216.83%.
• Zevra Therapeutics' Change in Acquisitions & Divestments stood at $300000.0 in 2022, then soared by 5108.33% to $15.6 million in 2023, then plunged by 98.71% to $202000.0 in 2024, then jumped by 43216.83% to $87.5 million in 2025, then gained by 7.4% to $94.0 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $94.0 million (Q1 2026), $87.5 million (Q4 2025), and $60.5 million (Q3 2025), per Business Quant data.